// App-Quantinova.ai

9026 : Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).

Researchers

Presenter

  • Rina Hui

Principal Investigators

  • Enric Carcereny Costa

  • Enriqueta Felip

  • Myung-Ju Ahn

  • Joseph Paul Eder

  • Ani Sarkis Balmanoukian

  • Natasha B. Leighl

  • Charu Aggarwal

  • Leora Horn

  • Amita Patnaik

  • Gary William Middleton

  • Matthew A. Gubens

  • Matthew David Hellmann

  • Jean-Charles Soria

  • Suresh S. Ramalingam

  • Gregory M. Lubiniecki

  • Jin Zhang

  • Bilal Piperdi

  • Edward B. Garon

Medical Centers

  • Westmead Hospital and University of Sydney, Sydney, Australia

  • Dana-Farber Cancer Institute, Boston, MA

  • Medical Oncology Department. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Yale University-Yale Cancer Center, New Haven, CT

  • The Angeles Clinic and Research Institute, Los Angeles, CA

  • Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, ON, Canada

  • University of Pennsylvania, Philadelphia, PA

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • START-South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX

  • University of Birmingham, Surrey, United Kingdom

  • University of California, San Francisco, San Francisco, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Merck & Co., Inc., Kenilworth, NJ

  • David Geffen School of Medcn at UCLA, Los Angeles, CA

Locations

  • Canada

  • Spain

  • United Kingdom

  • Australia

  • United States

  • France

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

  • Tissue polypeptide-specific antigen

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01295827

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved